UB researchers have published the first study comparing brain changes in patients who have MS or other neurological diseases, including Alzheimer’s and Parkinson’s.
The discovery of novel melatonin receptor molecules may make possible therapies for such circadian rhythm disburbances as jet lag, shift work, depression and sleep disorders.
The $21.7 million Clinical and Translational Science Award recognizes UB’s progress in bringing the benefits of clinical and translational science to patients.